Literature DB >> 2446753

Phase II trial of fludarabine phosphate in patients with head and neck cancer: a Southwest Oncology Group Study.

G B Weiss1, B Metch, D D Von Hoff, S A Taylor, J H Saiers.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2446753

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


× No keyword cloud information.
  6 in total

1.  Phase II trial of fludarabine phosphate (F-Ara-AMP) in patients with advanced head and neck cancer.

Authors:  A Mittelman; S Savona; C Puccio; H Chun; T Ahmed; E Feldman; P Sullivan; P Arnold; Z Arlin
Journal:  Invest New Drugs       Date:  1990       Impact factor: 3.850

Review 2.  Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy.

Authors:  S R Ross; D McTavish; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

Review 3.  Fludarabine phosphate. A new anticancer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma.

Authors:  G Rodriguez
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

4.  Fludarabine combined with radiotherapy in patients with locally advanced NSCLC lung carcinoma: a phase I study.

Authors:  Mirko Nitsche; Hans Christiansen; Katinka Lederer; Frank Griesinger; Heinz Schmidberger; Olivier Pradier
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-10       Impact factor: 4.553

5.  The Pro-Survival Oct4/Stat1/Mcl-1 Axis Is Associated with Poor Prognosis in Lung Adenocarcinoma Patients.

Authors:  Yu-Chu Su; Yi-Cheng Chen; Yau-Lin Tseng; Gia-Shing Shieh; Pensee Wu; Ai-Li Shiau; Chao-Liang Wu
Journal:  Cells       Date:  2021-10-03       Impact factor: 6.600

Review 6.  Marine Natural Products in Clinical Use.

Authors:  Neshatul Haque; Sana Parveen; Tingting Tang; Jiaen Wei; Zunnan Huang
Journal:  Mar Drugs       Date:  2022-08-18       Impact factor: 6.085

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.